title: Effect of Pollypill on cardiovascular parameters: Systematic review and meta-analysis.
abstract: BACKGROUND
  Wald and law in their landmark paper published in BMJ in 2003 hypothesized that the use of fixed dose combination of statins, beta blockers, angiotensin-converting-enzyme inhibitor (ACE) inhibitor, and aspirin (Pollypill) may decrease cardiovascular disease by >80% if Pollypills are used as primary prevention. Many clinical trials were started to test this hypothesis. The present systematic review and meta-analysis aims to assess the available clinical trials to see the effect of Pollypill on cardiovascular mortality and on other risk factors that linked with increase in cardiovascular events.
  
  
  METHODS
  Available databases were searched with different specific terms and combination of key words. All randomized clinical trials exploring the effect of Pollypill on various cardiovascular parameters were included in the analysis. Primary endpoints as decided were cardiovascular mortality, systolic blood pressure, diastolic blood pressure, and low-density lipoprotein (LDL) cholesterol. Effect of Pollypill on high-density lipoprotein (HDL) cholesterol, total cholesterol, triglycerides, the number of participants who discontinued treatment, and the number of participants who experienced side effects were measured and analyzed as secondary outcomes. Both fixed and random models were used for analysis. Analysis was performed by comprehensive meta-analysis software.
  
  
  RESULTS
  Six trials were included in systematic review. It was observed that Pollypill decreases systolic and diastolic blood pressure (P = 0.000). Pollypill was also found to decrease LDL cholesterol, total cholesterol, and triglyceride as compared to the control (all P = 0.000); however, there was no significant improvement in HDL (P = 0.39). The number of participants in whom side effects were observed were found to be more in the Pollypill group (odds ratio = 1.73, P = 0.000). It was also observed that dropouts were more in the Pollypill group than in the control group (odds ratio = 1.48, P = 0.02). Due to the lack of sufficient data effect of Pollypill, cardiovascular mortality could not be assessed.
  
  
  CONCLUSIONS
  Pollypill decreases various surrogate endpoints related to cardiovascular outcome, but with the increased chance of side effects as compared to control.
authors.affiliation: Department of Pharmacology, Government Medical College, Surat, Gujarat 395001, India.
authors.forename: Jaykaran
authors.initials: J
authors.lastname: Charan
authors.forename: Jagdish Prasad
authors.initials: JP
authors.lastname: Goyal
authors.forename: Deepak
authors.initials: D
authors.lastname: Saxena
keywords: Clinical trials; Diastolic blood pressure; Low-density lipoprotein cholesterol; Pollypill; Systolic blood pressure
references.citation: Circulation. 2010 Nov 16;122(20):2078-88
references.pmid: 21098469
references.citation: PLoS Med. 2009 Jul 21;6(7):e1000100
references.pmid: 19621070
references.citation: Indian J Pharmacol. 2009 Feb;41(1):54
references.pmid: 20177585
references.citation: PLoS One. 2011;6(5):e19857
references.pmid: 21647425
references.citation: PLoS One. 2012;7(7):e41297
references.pmid: 22815989
references.citation: Lancet. 2005 Oct 8;366(9493):1267-78
references.pmid: 16214597
references.citation: Int J Clin Pract. 2010 Aug;64(9):1220-7
references.pmid: 20653798
references.citation: Am Heart J. 2006 Jan;151(1):185-91
references.pmid: 16368315
references.citation: BMJ. 2002 Jan 12;324(7329):71-86
references.pmid: 11786451
references.citation: Trials. 2011 Jan 05;12:3
references.pmid: 21205325
references.citation: JAMA. 2003 May 21;289(19):2534-44
references.pmid: 12759325
references.citation: Ann Intern Med. 1996 Oct 1;125(7):605-13
references.pmid: 8815760
references.citation: BMJ. 2011 Jul 22;343:d4002
references.pmid: 21784880
references.citation: Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):463-71
references.pmid: 22787067
references.citation: Lancet. 2009 Apr 18;373(9672):1341-51
references.pmid: 19339045
references.citation: BMJ. 2003 Jun 28;326(7404):1419
references.pmid: 12829553
references.citation: Eur J Clin Nutr. 2005 Aug;59 Suppl 1:S4-8; discussion S9
references.pmid: 16052194